Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisD

Health Canada to publish reasons for drug approvals

Laura Eggertson
CMAJ May 24, 2005 172 (11) 1431; DOI: https://doi.org/10.1503/cmaj.050506
Laura Eggertson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Health Canada will launch a new database this summer to provide health care professionals and the public with information about all drugs approved in Canada since 1994.

The searchable, bilingual database will list Notices of Compliance (NOC) as well as summaries of the basis for Health Canada's approval of the drugs. “It will be the most comprehensive source of Canadian NOC data ever available,” Federal Health Minister Ujjal Dosanjh said.

The database, to be posted on Health Canada's Web site, will include the name of each drug, its therapeutic class, its active or medicinal ingredient, when it was approved, its form and how it is administered.

“As long as we protect the proprietary information that companies provide Health Canada, people have a right to know the basis on which we evaluate drug submissions,” Dosanjh told the Canadian Therapeutics Congress in Vancouver in April.

With or without an early election, the database will proceed and be launched when it is ready, says Health Canada spokesperson Jirina Vlk.

The database is one in a series of measures Dosanjh announced to try to improve what he called “a system of therapeutic safety that is already one of the best in the world.” An ombudsman's office will open this summer to “assist in resolving disputes” about the way Health Canada fulfils its responsibilities under the Food and Drugs Act.

The new Office of Paediatric Initiatives will coordinate dialogue among experts interested in nutrition, as well as the safety of food, drugs, medical devices and vaccines for children. Career public servant Linda Barber became executive director Mar. 4 and will hire a senior medical advisor. “For the first time ... we're going to have a central co-ordinating point for pediatric needs and information,” says Barber.

Though the office will be small and will not have a budget for original research, Barber hopes to create incentives for pharmaceutical companies to share existing data or conduct trials on drugs prescribed to children.

Dosanjh has also promised a permanent Drug Safety Board that would permit Canadians and health care practitioners to provide input into drugs both before and after they are approved.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (11)
CMAJ
Vol. 172, Issue 11
24 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Health Canada to publish reasons for drug approvals
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Health Canada to publish reasons for drug approvals
Laura Eggertson
CMAJ May 2005, 172 (11) 1431; DOI: 10.1503/cmaj.050506

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Health Canada to publish reasons for drug approvals
Laura Eggertson
CMAJ May 2005, 172 (11) 1431; DOI: 10.1503/cmaj.050506
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Canadian government
    • Drug regulation

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire